Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX

Crinetics Pharmaceuticals — Corporate Update (April 2020)

9 slides from Crinetics Pharmaceuticals's corporate update, Apr 6, 2020

  1. Slide 1: Interim Results from the Open Label ACROBAT Edge Phase 2 Study and Corporate Update

    Interim Results from the Open Label ACROBAT Edge Phase 2 Study and Corporate Update Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    SAFE HARBOR STATEMENT This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statements regarding: the potential for interim data results to be replicated or continue to

  3. Slide 3: Corporate update: Paltusotine Phase 2 acromegaly program achieves key milestones

    Corporate update Paltusotine Phase 2 acromegaly program achieves key milestones Interim results from Edge patients who completed participation by Feb 23, 2020 showed that after 13 weeks, patients who were switched to once daily oral paltusotine maintained IGF-1 levels that were achieved with prior i

  4. Slide 4: ACROBAT Edge design

    Group Patient Groups IGF-1 range # of Patients 1 Octreotide LAR or lanreotide depot > 1.0x ULN to ≤ 2.5x ULN At least 30 2 Dopamine agonist + octreotide LAR or lanreotide depot > 1.0x ULN to ≤ 2.5x ULN 3 Dopamine agonist + octreotide LAR or lanreotide depot ≤ 1.0x ULN Max 15 4 Pasireotide LAR ≤ 1.0x

  5. Slide 5: Edge interim data cut as of February 23, 2020

    Group 1 (N=13) Total (N=32) Median Age, years (Min, Max) 53.0 (34, 68) 51.5 (34, 70) Sex Female 7 (53.8%) 19 (59.4%) Male 6 (46.2%) 13 (40.6%) Ethnicity Hispanic or Latino 0 6 (18.8%) Not Hispanic or Latino 13 (100%) 26 (81.3%) Race White 13 (100%) 29 (90.6%) Black or African American 0 1 (3.1%) Oth

  6. Slide 6: Paltusotine maintained baseline IGF-1 and integrated GH levels 13 weeks after switching

    Paltusotine maintained baseline IGF-1 and integrated GH levels 13 weeks after switching from injected depot therapy Both IGF-1 and GH levels promptly rose after paltusotine withdrawal Data shown are median (25th percentile, 75th percentile) for Group 1 patients *Data includes two early termination (

  7. Slide 7: Change in serum hormone levels and efficacy conclusions

    Parameter (units) Change in Serum Hormone Levels Change from Baseline to EoT (Week 13) Change from EoT to Post Withdrawal Visit 2 Weeks 4 Weeks IGF-1 (×ULN) N=13 N=12 N=11 Mean (95% CI) -0.015 (-0.123, 0.092) 0.739 (0.394, 1.083) 0.767 (0.379, 1.155) Median (25th, 75th percentiles) -0.047 (-0.102, 0

  8. Slide 8: Switching to oral paltusotine maintained IGF-1 levels in over 90% of completers

    EoT=End of Treatment; WD=Withdrawal *Data includes two early termination (ET) patients who discontinued for non-study drug related reasons and had 16 days (~2 weeks) and 23 days (~3 weeks) of paltusotine exposure. 1 ET patient had final assessment 2 weeks after EoT (GH data from this subject was inc

  9. Slide 9: Paltusotine was safe and well tolerated

    Preferred Term Group 1 (N=13) n (%) Total (N=32) n (%) Number (%) of Patients with any TEAEs 9 (69%) 14 (44%) Arthralgia 3 (23%) 6 (19%) Headache 4 (31%) 5 (16%) Abdominal discomfort 1 (8%) 3 (9%) Peripheral swelling 2 (15%) 3 (9%) Back pain 2 (15%) 2 (6%) Diarrhoea 0 2 (6%) Flatulence 0 2 (6%) Hype

Crinetics Pharmaceuticals — Corporate Update (April 2020) on 6ix